Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial - 06/08/11
, P. Gabriel Steg, MD d, k, Steven R. Steinhubl, MD e, k, Gilles Montalescot, MD, PhD f, k, Mingyuan Shao, MS g, k, Werner Hacke, MD h, k, Keith A. Fox, MBChB i, k, Peter B. Berger, MD e, k, Eric J. Topol, MD j, k, A. Michael Lincoff, MD g, kRiassunto |
Background |
The association between bleeding severity and cause of mortality in the non-acute setting is unclear. We sought to investigate the association between bleeding and mortality subtype, and assess whether this association differs in patients on dual antiplatelet therapy (DAPT) versus aspirin alone.
Methods |
Using multivariable Cox proportional hazards survival regression, we examined the association between moderate or severe bleeding and all-cause, cardiovascular, and cancer mortality in 15,603 patients with cardiovascular disease or multiple risk factors enrolled in the CHARISMA trial.
Results |
Patients with moderate or severe bleeding had a higher incidence of all-cause, cardiovascular, and cancer mortality (P < .001 for each). After multivariable adjustment, moderate/severe bleeding remained independently associated with not only all-cause mortality (adjusted hazard ratio [HR] 1.66; 95% confidence interval [CI] 1.24-2.21) and cardiovascular mortality (HR 2.05, 95% CI 1.38-3.04) but also cancer mortality (HR 4.76, 95% CI 2.60-8.69). However, there was a significant interaction between bleeding and potency of antiplatelet therapy for all-cause (P = .002), cardiovascular (P = .02), and cancer mortality (P = .03); in subjects on aspirin alone, moderate/severe bleeding was associated with all-cause (HR 5.27, 95% CI 3.56-7.80), cardiovascular (HR 4.33, 95% CI 2.55-7.37), and cancer mortality (HR 9.01, 95% CI 4.41-18.43), but not in subjects on DAPT (all-cause: HR 1.48, 95% CI 0.93-2.34; cardiovascular: HR 1.04, 95% CI 0.58-1.86; and cancer mortality: HR 1.79, 95% CI 0.56-5.74).
Conclusions |
In stable patients, moderate or severe bleeding is associated with a significantly increased risk of all-cause, cardiovascular, and cancer mortality. However, this risk appeared different in subjects on single antiplatelet therapy versus DAPT.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 162 - N° 1
P. 98 - luglio 2011 Ritorno al numero
Articolo precedente
- Cardiogenic shock and heart failure post–percutaneous coronary intervention in ST-elevation myocardial infarction: Observations from “Assessment of Pexelizumab in Acute Myocardial Infarction”
- John K. French, Paul W. Armstrong, Eric Cohen, Neal S. Kleiman, Christopher M. O'Connor, Anne S. Hellkamp, Amanda Stebbins, David R. Holmes, Judith S. Hochman, Christopher B. Granger, Kenneth W. Mahaffey
- Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial
- Michelle A. Albert, Robert J. Glynn, Francisco A.H. Fonseca, Alberto J. Lorenzatti, Keith C. Ferdinand, Jean G. MacFadyen, Paul M Ridker
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?